Kimberly Harrow

485 total citations
26 papers, 234 citations indexed

About

Kimberly Harrow is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Kimberly Harrow has authored 26 papers receiving a total of 234 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Kimberly Harrow's work include Lung Cancer Treatments and Mutations (25 papers), Pancreatic and Hepatic Oncology Research (10 papers) and Cancer Mechanisms and Therapy (9 papers). Kimberly Harrow is often cited by papers focused on Lung Cancer Treatments and Mutations (25 papers), Pancreatic and Hepatic Oncology Research (10 papers) and Cancer Mechanisms and Therapy (9 papers). Kimberly Harrow collaborates with scholars based in United States, Hong Kong and China. Kimberly Harrow's co-authors include Gary Dukart, Heather A. Wakelee, Jeffrey R. Infante, Chris Liang, George R. Blumenschein, Christine M. Lovly, Karen L. Reckamp, Joel W. Neal, Saiama N. Waqar and James J. Gibbons and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Kimberly Harrow

22 papers receiving 230 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kimberly Harrow United States	6	204	177	104	31	15	26	234
Masayoshi Miyawaki Japan	5	226 1.1×	180 1.0×	121 1.2×	44 1.4×	23 1.5×	7	261
Yasunari Kishino Japan	10	182 0.9×	147 0.8×	107 1.0×	25 0.8×	23 1.5×	15	268
Evan Rogers United States	8	188 0.9×	154 0.9×	142 1.4×	52 1.7×	27 1.8×	25	267
Rossella Messina United States	3	233 1.1×	182 1.0×	75 0.7×	55 1.8×	27 1.8×	6	269
Masayuki Yasugi Japan	9	241 1.2×	240 1.4×	132 1.3×	48 1.5×	38 2.5×	22	358
J.C.-H. Yang Taiwan	5	281 1.4×	263 1.5×	94 0.9×	46 1.5×	22 1.5×	12	353
Marc Chioda United States	9	185 0.9×	181 1.0×	77 0.7×	42 1.4×	25 1.7×	14	276
Diana Gernhardt United States	7	200 1.0×	248 1.4×	135 1.3×	56 1.8×	12 0.8×	8	338
L. Paz-Ares Spain	9	215 1.1×	291 1.6×	97 0.9×	40 1.3×	38 2.5×	51	374
Maciej Bryl Poland	9	117 0.6×	176 1.0×	72 0.7×	49 1.6×	17 1.1×	32	273

Countries citing papers authored by Kimberly Harrow

Since Specialization

Citations

This map shows the geographic impact of Kimberly Harrow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberly Harrow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberly Harrow more than expected).

Fields of papers citing papers by Kimberly Harrow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimberly Harrow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberly Harrow. The network helps show where Kimberly Harrow may publish in the future.

Co-authorship network of co-authors of Kimberly Harrow

This figure shows the co-authorship network connecting the top 25 collaborators of Kimberly Harrow. A scholar is included among the top collaborators of Kimberly Harrow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberly Harrow. Kimberly Harrow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wakelee, Heather A., Karen L. Reckamp, Ticiana Leal, et al.. (2019). P1.14-32 Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer Patients Treated with Ensartinib. Journal of Thoracic Oncology. 14(10). S566–S566. 2 indexed citations

Whisenant, Jonathan, Kathryn E. Beckermann, Hossein Borghaei, et al.. (2019). P1.04-17 Phase I/II Study of Nivolumab and Vorolanib in Patients with Refractory Thoracic Tumors. Journal of Thoracic Oncology. 14(10). S445–S446. 1 indexed citations

Kim, Hyeon Woo, Kimberly Harrow, Giovanni Selvaggi, et al.. (2019). P1.14-57 Post-Ensartinib Outcomes in Refractory Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 14(10). S577–S578.

Horn, Leora, Jennifer G. Whisenant, Heather A. Wakelee, et al.. (2019). Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC). Annals of Oncology. 30. ii48–ii48. 2 indexed citations

Horn, Leora, Jeffrey R. Infante, Karen L. Reckamp, et al.. (2018). Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clinical Cancer Research. 24(12). 2771–2779. 131 indexed citations

Horn, Leora, Yi‐Long Wu, Martin Reck, et al.. (2018). P1.13-02 eXalt3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients. Journal of Thoracic Oncology. 13(10). S582–S582. 1 indexed citations

Horn, Leora, Yi‐Long Wu, Martin Reck, et al.. (2018). 194TiP eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients. Journal of Thoracic Oncology. 13(4). S116–S116. 2 indexed citations

Bendell, Johanna C., Kathleen N. Moore, Manish R. Patel, et al.. (2018). A phase I trial of vorolanib (X-82t vascular endothelial growth factor receptor (VEGFR) inhibitor, in patients (pts) with advanced solid tumors. Annals of Oncology. 29. viii659–viii660.

Horn, Leora, Yi‐Long Wu, Martin Reck, et al.. (2018). eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology. 36(15_suppl). TPS9115–TPS9115. 3 indexed citations

10.

Horn, Leora, Yi‐Long Wu, Martin Reck, et al.. (2018). eXalt3: Phase III randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients. Annals of Oncology. 29. viii543–viii543. 2 indexed citations

11.

Reckamp, Karen L., Heather A. Wakelee, Sandip Pravin Patel, et al.. (2017). CNS activity of ensartinib in ALK+ non-small cell lung cancer (NSCLC) patients (pts). Annals of Oncology. 28. ii31–ii32. 3 indexed citations

12.

Wu, Yi‐Long, Tony Mok, Martin Reck, et al.. (2017). P2.04-012 First-Line Ensartinib (X396) versus Crizotinib in Advanced ALK-Rearranged NSCLC (eXalt3): A Randomized, Open-Label, Phase 3 Study. Journal of Thoracic Oncology. 12(11). S2402–S2402.

13.

Horn, Leora, Heather A. Wakelee, Karen L. Reckamp, et al.. (2017). P3.02a-001 Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC. Journal of Thoracic Oncology. 12(1). S1159–S1159. 5 indexed citations

14.

Horn, Leora, Yi‐Long Wu, Martin Reck, et al.. (2017). eXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 35(15_suppl). TPS8578–TPS8578. 5 indexed citations

15.

Wakelee, Heather A., Rachel E. Sanborn, Jorge J. Nieva, et al.. (2017). MA 07.02 Response to Ensartinib in TKI Naïve ALK+ NSCLC Patients. Journal of Thoracic Oncology. 12(11). S1826–S1826. 3 indexed citations

16.

Horn, Leora, Karen L. Reckamp, Sandip Pravin Patel, et al.. (2017). Abstract CT151: CNS activity of ensartinib in ALK-positive non-small cell lung cancer patients. Cancer Research. 77(13_Supplement). CT151–CT151. 2 indexed citations

17.

Wakelee, Heather A., Jeffrey R. Infante, George R. Blumenschein, et al.. (2016). P1.44 (also presented as PD2.02): Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK+ NSCLC. Journal of Thoracic Oncology. 11(10). S209–S210. 3 indexed citations

18.

Horn, Leora, Heather A. Wakelee, Karen L. Reckamp, et al.. (2016). MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC. Journal of Thoracic Oncology. 11(11). S256–S257. 7 indexed citations

19.

Reckamp, Karen L., Jeffrey R. Infante, George R. Blumenschein, et al.. (2016). Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 11(2). S36–S37. 8 indexed citations

20.

Wakelee, Heather A., George Blumenschein, Karen L. Reckamp, et al.. (2016). Phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx). Annals of Oncology. 27. vi419–vi419. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact